Complications of androgen deprivation therapy in men with prostate cancer

被引：26

作者：

Chen A.C. ^{[1
]}

Petrylak D.P. ^{[1
]}

机构：

[1] Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032

来源：

Current Oncology Reports | 2004年 / 6卷 / 3期

关键词：

Prostate Cancer; Zoledronic Acid; Androgen Deprivation Therapy; Advanced Prostate Cancer; Gynecomastia;

D O I：

10.1007/s11912-004-0051-0

中图分类号：

学科分类号：

摘要：

Androgen deprivation therapy (ADT) is indicated for the treatment of metastatic prostate cancer and locally advanced disease. In addition to sexual side effects, long-term ADT results in several other changes, including hot flashes; gynecomastia; changes in body composition, metabolism, and the cardiovascular system; osteoporosis; anemia; psychiatric and cognitive problems; and fatigue and diminished quality of life. This review discusses these complications of ADT and treatments aimed at reducing them. It is important for clinicians to anticipate these effects and to initiate measures to prevent or minimize them in order to maintain quality of life in prostate cancer survivors. Copyright © 2004 by Current Science Inc.

引用

页码：209 / 215

页数：6

共 59 条

[1]

Caubet J.F., Tosteson T.D., Dong E.W., Et al., Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens, Urology, 49, pp. 71-78, (1997)

[2]

Bolla M., Collette L., Blank L., Et al., Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial, Lancet, 360, pp. 103-108, (2002)

[3]

Messing E.M., Manola J., Sarosdy M., Et al., Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer, N. Engl. J. Med., 341, pp. 1781-1788, (1999)

[4]

Herr H.W., O'Sullivan M., Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy, J. Urol., 163, pp. 1743-1746, (2000)

[5]

Potosky A.L., Knopf K., Clegg L.X., Et al., Quality-of-life outcomes after primary androgen deprivation therapy: Results from the Prostate Cancer Outcomes Study, J. Clin. Oncol., 19, pp. 3750-3757, (2001)

[6]

Fowler F.J., Collins M.M., Corkery E.W., Et al., The impact of androgen deprivation on quality of life after radical prostatectomy for prostate adenocarcinoma, Cancer, 95, pp. 287-295, (2002)

[7]

Potosky A.L., Reeve B.B., Clegg L.X., Et al., Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy, J. Natl. Cancer Inst., 94, pp. 430-437, (2002)

[8]

Iversen P., Tyrrell C.J., Kaisary A.V., Et al., Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup, J. Urol., 164, pp. 1579-1582, (2000)

[9]

Gleave M., Goldenberg S.L., Bruchovsky N., Rennie P., Intermittent androgen suppression for prostate cancer: Rationale and clinical experience, Prostate Cancer Prostatic Dis., 1, pp. 289-296, (1998)

[10]

Kouriefs C., Georgiou M., Ravi R., Hot flushes and prostate cancer: Pathogenesis and treatment, BJU Int., 89, pp. 379-383, (2002)

← 1 2 3 4 5 6 →